Search
Clene Inc.
CLNNAdd to Watchlist
6.100USD
-0.030-0.49%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
71.85MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.49%
5 Days
+5.35%
1 Month
+3.92%
6 Months
+5.72%
Year to Date
+3.92%
1 Year
+54.43%
Key Figures
6.200Open
6.422High
30.04KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.26%Turnover Ratio
6.130Prev. Close
6.030Low
120.87KTurnover
LossP/E Static
-3.82P/B
0.00%Div Yield TTM
-142.67%ROA
13.50052wk High
0.65Volume Ratio
-39.40MNet Profit
11.78MShares
-3.2645EPS TTM
0.92Beta
-1738.36%ROE
2.60052wk Low
6.39%Amplitude
100.00%Gross Margin
71.85MMarket Cap
0.96Reward/Risk
6.72%Risk Rate
TradingKey Stock Score of Clene Inc.
Currency: USD Updated: 2026-07-02Key Insights
Clene Inc.'s fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 169 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 32.20.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Clene Inc.'s Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Clene Inc. Highlights
StrengthsRisks
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Growing
The company is in a growing phase, with the latest annual income totaling USD 200.00K.
Fairly Valued
The company’s latest PE is -1.87, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.19M shares, decreasing 1.60% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.84.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
32.200
Target Price
+408.29%
Upside Space
Clene Inc. News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Clene Inc. Info
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
Ticker SymbolCLNN
CompanyClene Inc.
CEOEtherington (Robert)
Websitehttps://clene.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52804.200
-38.300 (-0.07%)
29658.800
+347.400 (+1.19%)
7502.300
+30.800 (+0.41%)
14964.000
+161.000 (+1.09%)
69531.000
+1383.000 (+2.03%)
6395.900
+43.100 (+0.68%)
68.163
-0.181 (-0.27%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.790
+52.880 (+1.28%)
FAQs
What is the current price of Clene Inc. (CLNN)?
The current price of Clene Inc. (CLNN) is 6.10.
What is the symbol of Clene Inc.?
The ticker symbol of Clene Inc. is CLNN.
What is the 52-week high of Clene Inc.?
The 52-week high of Clene Inc. is 13.50.
What is the 52-week low of Clene Inc.?
The 52-week low of Clene Inc. is 2.60.
What is the market capitalization of Clene Inc.?
The market capitalization of Clene Inc. is 77.95M.
Is Clene Inc. (CLNN) currently rated as Buy, Hold, or Sell?
According to analysts, Clene Inc. (CLNN) has an overall rating of Buy, with a price target of 32.20.
What is the Earnings Per Share (EPS TTM) of Clene Inc. (CLNN)?
The Earnings Per Share (EPS TTM) of Clene Inc. (CLNN) is -2.65.